• UCB SA, of Brussels, Belgium, said a subgroup analysis of pooled data from three long-term open-label extension trials showed a consistent safety profile with epilepsy drug Vimpat (lacosamide), with the most commonly reported treatment-emergent adverse events being dizziness, headache and nasopharyngitis. Read More
• NeuroVive Pharmaceutical AB, of Lund, Sweden, said Phase I data published in Clinical Drug Investigation showed that its CicloMulsion, a Cremophor-free intravenous cyclosporine formula, was bioequivalent to Sandimmune injection and was safe and well tolerated. Read More
• Galena Biopharma Inc., of Lake Oswego, Ore., partnered with Teva Pharmaceutical Industries Ltd., of Petach Tikva, Israel, to commercialize an investigational breast cancer vaccine, NeuVax (nelipepimut-S), in Israel. Read More
Privately held Zafgen Inc. secured a hefty Series D equity raise of $21 million, which will move obesity candidate beloranib (ZGN-440) beyond the Phase IIa trial that was initiated last month. Read More
In a decision hailed by some as a free-speech victory and by others as a ruling that gives drugmakers free rein to promote their goods off-label, federal appeals judges threw out the conviction of a former sales representative with Orphan Medical Inc. (acquired by Jazz Pharmaceuticals plc), who claimed his First Amendment rights were violated. Read More
Shares of Geron Corp. fell 23 percent Tuesday on news that the Menlo Park, Calif.-based company discontinued development of its brain cancer drug GRN1005. Read More
The secretive backers of Cardiorentis Ltd. prefer to remain anonymous, but they obviously are expecting to see the name of the company's main asset, Ularitide, in lights, having made a €100 million (US$130.6 million) investment to put the product through a Phase III trial in treating 2,116 patients with acute heart failure. Read More
